Skip to main content
. 2015 Mar 13;350:h1046. doi: 10.1136/bmj.h1046

graphic file with name scod018904.f2_default.jpg

Fig 2 Observed treatment differences for primary and secondary outcome measures in study in patients with rheumatoid arthritis randomised to treatment with combinations of disease modifying drugs or tumour necrosis factor inhibitors. Scales and direction of change for different outcome measures vary: health assessment questionnaire ranges from 0-3, higher scores are worse, and positive differences favour tumour necrosis factor strategy; EQ5D-3L ranges from 0-1, higher scores are better, and negative differences favour tumour necrosis factor strategy; SF-36 physical component score and mental component score range from 0-100, higher scores are better, and negative differences favours tumour necrosis factor strategy; Larsen score ranges from 0-200, higher scores are worse, and positive differences favours tumour necrosis factor strategy